Kornimate/medical-research-clean huggingface dataset:
differences in access to emergency paediatric intensive care and care during transport

Conditions: Access and Transport to Paediatric Intensive Care

Summary: there are fewer than 30 paediatric intensive care units (picus) in the united kingdom (uk). this means that a critically ill child taken to their nearest hospital will need to be transferred to a picu. such transports are usually done by picu retrieval teams (picrts), mobile teams who take specialist expertise to the child and safely transport them to a picu. there are national variations in how picrts are organised and deliver clinical care. there has been little research into these differences and how they might influence outcomes and experiences for sick children and families. the investigators do not know if national variation in how picrt services are organised and delivered matters, or whether current standards help achieve the best outcomes for patients. this clinical study aims to understand how existing differences in access to paediatric intensive care and care provided by picrts affect clinical outcomes and experiences for transported critically ill children and families. the investigators will analyse routine national audit data to examine various aspects such as how long it takes a picrt to reach the patient, how long it takes the child to reach the picu, the seniority of clinicians performing the transport, medical procedures performed by the picrt and any critical incidents during transport, and investigate whether any of these factors influence how likely a child is to survive. the investigators will also collect and analyse information about the experiences of sick children by interviewing the families involved, and staff experiences of picu retrieval by interviewing clinicians. alongside this work, the investigators will look at the costs of different ways of delivering picrt services for sick children, and use mathematical techniques to study if and how alternate models of service delivery can improve clinical outcomes in a cost effective manner. the research team in this trial includes picu and transport clinicians, parents, academic experts and an national health service (nhs) commissioner. independent committees consisting of clinicians and parents will be formed to oversee the study. the work from this study will directly inform the development of evidence-based national standards for picu transport and help improve the patient experience for critically ill children and their families.


Eligibility criteria:
inclusion criteria: * children and young people (age \<16 years) transported by a pic retrieval team for emergency admission to a paediatric intensive care unit in england and wales. exclusion criteria: * none

Keywords: paediatric critical care transport
fungemia in hematologic malignancies

Conditions: Acute Leukemia; Chronic Leukemia; Multiple Myeloma; Lymphoma

Summary: the purpose of this study is to determine the risk factors for fungemia in a population of patients diagnosed with hematologic malignancies and eligible for chemotherapy.

the coordinating center provides all participating centers with an epidemiologic form, in order to collect data in a comparable way. the requested informations include type of malignancy and its treatment, environmental expositions, laboratory work up, antifungal prophylaxis, clinical signs of infection, microbiological findings, antifungal therapy and outcome of infection at 30 days. the planned sample size is about 300 patients to be recruited in 35 participating center over 5 years, in a retrospective-prospective fashion. data check will be performed at the coordinating center. missing data will be managed to minimize incomplete reports. statistical analysis will be performed by an independent reviewer, in order to assess risk factors predictive of fungal infection and outcome.

Eligibility criteria:
inclusion criteria: * patients diagnosed with hematologic malignancies and eligible to chemotherapy exclusion criteria: * patients not eligible to chemotherapy

Keywords: fungemia hematologic malignancies
safety and efficacy of chocolate balloon catheter in peripheral arterial disease (choco-pad)

Conditions: Peripheral Arterial Disease

Summary: this study aims to learn about the long-term safety and effectiveness of the chocolate balloon catheter in patients with blocked leg arteries (peripheral artery disease, or pad). the chocolate balloon is a special type of balloon used during minimally invasive procedures to open narrowed arteries while potentially causing less damage to the blood vessel. the main question it aims to answer is: does the chocolate balloon keep the treated artery open after 12 months without needing repeat procedures? patients with pad who are already scheduled to undergo an artery-opening procedure (angioplasty) with the chocolate balloon as part of their standard care will answer the question about the safety and effectiveness of the chocolate balloon catheter


Eligibility criteria:
inclusion criteria: * participant or legal guardian provides written informed consent. * age ≥18 and ≤80 years, regardless of gender. * de novo target lesion located in the native superficial femoral, popliteal, or infrapopliteal artery. * life expectancy \>1 year as assessed by the investigator. * candidate suitable for endovascular angiography and intervention per investigator judgment. * willingness to undergo chocolate balloon catheter pta. exclusion criteria: * active systemic infection or uncontrolled coagulation disorder within 14 days prior to procedure. * planned major amputation of the target limb (at or above the ankle). * renal insufficiency (mdrd egfr ≤30 ml/min/1.73 m²) or serum creatinine ≥2.5 mg/dl within 30 days, or dialysis dependence. * contraindication to antiplatelet therapy (aspirin/clopidogrel), low-molecular-weight heparin, vasodilators, or contrast agents. * uncontrolled systemic comorbidities (e.g., severe cardiac/pulmonary/hepatic dysfunction, advanced malignancy, uncorrected coagulopathy). * history of cerebral hemorrhage, symptomatic stroke, myocardial infarction, or gastrointestinal bleeding within 6 months. * pregnancy, lactation, or planned pregnancy (men or women). * participation in another interventional clinical trial with unmet primary endpoint. * investigator-determined medical, social, or psychological contraindications. * life expectancy \<1 year.

Keywords: chocolate balloon catheter percutaneous transluminal angioplasty peripheral arterial disease
transcranial alternating current stimulation for hand function recovery

Conditions: Stroke

Summary: tacs has the potential to directly induce cortical alterations in the intrinsic neural oscillation at specific frequencies, and the brain could mirror the induced frequencies of the external source of oscillations from the stimulation. hence, tacs with matching stimulation frequency could be an effective means of enhancing brain oscillatory activity to potentially induce synaptic plasticity for restoration of damaged brain functions. however from the existing studies of applying tacs over the m1 in healthy and diseased brains, there is a wide range of applied stimulation frequencies and varied neuromodulation effects on motor behavior or cortical excitability at different frequencies. in this proposal, subject-specific stimulation frequency and latency will be identified.


Eligibility criteria:
inclusion criteria: * hemiparesis subsequent to first-ever unilateral stroke for more than 6 months; * mcp and pip finger joints can be extended to 180° passively; * sufficient cognition to follow the experimental instructions exclusion criteria: * severe hand spasticity or hand deformity; * history of alcohol or drug abuse or epilepsy; * bilateral brain infarcts; * severe cognitive deficits; * comprehensive aphasia; * contraindications to tacs and mri
candin safety & efficacy study for the treatment of warts

Conditions: Warts; Human Papilloma Virus

Summary: the primary objective of this study is to determine the safety of candin® (candida albicans skin test antigen) at a 0.3 ml dose level at up to 6 monthly injections for treating common warts (verruca vulgaris).

the primary objective of this study is to determine the safety of candin® (candida albicans skin test antigen) at either 0.3 ml dose levels at up to 6 monthly injections (a maximal, cumulative dose of 1.9 ml, including the delayed-type hypersensitivity (dth) test) for treating common warts (verruca vulgaris). a secondary objective is to understand the relative effectiveness of the 0.3 dose level for treating common warts, both those that were injected and those that were not injected as well as other types of warts that were not injected to allow a determination of appropriate dose levels to use in a future dose-ranging efficacy trial.

Eligibility criteria:
inclusion criteria: * must have at least 3 and not more than 10 common warts not located on the palms or digits * positive dth response to candin® required exclusion criteria: * no previous medical treatment for warts other than otc * no immunocompromising medical conditions or medicines allowed * no preexisting inflammatory conditions at treatment site allowed

Keywords: treatment common wart lesions (verruca vulgaris)
study of allogeneic adipose-derived mesenchymal stem cells to treat post covid-19 "long haul" pulmonary compromise

Conditions: Covid19

Summary: this is a phase 1b study to assess the safety and efficacy of covi-msc in treating post covid-19 "long haulers" with pulmonary compromise.

this is a phase 1b multicenter study to assess the safety and efficacy of covi-msc in treating post covid-19 "long haulers" with pulmonary compromise. covi-msc will be administered intravenously on day 0, day 2, and day 4.

Eligibility criteria:
inclusion criteria: * has had prior laboratory-confirmed sars-cov-2 infection as determined by an approved polymerase chain reaction (pcr) or an approved antigen test of any specimen * has had a recent (within a week) negative sars-cov-2 test (an approved pcr or antigen test) * has had at least moderate or severe post-covid-19 pulmonary symptoms for at least 3 months which have resulted in reduced physical functioning compared to pre-covid-19 status * willing to follow contraception guidelines exclusion criteria: * clinically improving pulmonary status over the month prior to screening * undergone a previous stem cell infusion unrelated to this trial * pregnant or breast feeding or planning for either during the study * suspected uncontrolled active bacterial, fungal, viral, or other infection * history of a splenectomy, lung transplant or lung lobectomy * concurrent participation in another clinical trial involving therapeutic interventions (observational study participation is acceptable)

Keywords: covid-19 long haul post-acute covid
posterior tibial artery perforator-pedicled propeller flaps in reconstruction

Conditions: Trauma Patients with Soft Tissue Defects

Summary: soft tissue defects in the lower leg remain a challenge for surgeons due to frequent bone exposure and paucity of soft tissues. the goal in this study was to evaluate the surgical technique and clinical significance of posterior tibial artery perforator-pedicled propeller flaps for reconstruction of defects in the lower leg.

the construction of the lower extremity defects with exposed bone and tendon is considered as the biggest challenge of all body regions in many plastic and reconstructive surgeons. the lower leg regions are in visible areas. defects recovery and aesthetic consideration should be considered at the same time with the development of the economy and society. although free flaps have been used to reconstruct these defects, some disadvantages still exist, such as needing microinstruments, long operation time and none like-with-like repair. in this article, a series of patients with soft tissue defects in the lower leg were transplanted with posterior tibial artery perforator-pedicled propeller flaps.

Eligibility criteria:
inclusion criteria: * 1.age range :10-80years. 2. in good overall heath without severe comorbidities. 3. posterior perforator tibial artery is no damage. exclusion criteria: 1. age range \ 80years. 2. with severe comorbidities 3. posterior perforator tibial artery of panticipants is damage

Keywords: the lower leg soft tissue defects perforator flaps propeller flaps doppler ultrasound
"platelet rich plasma for the management of post-viral olfactory dysfunction.

Conditions: Olfactory Disorder; Olfaction Disorders

Summary: sars cov-19 has resulted in prolonged olfactory dysfunction in many patients. the investigators aim to compare the effect of topical platelet-rich plasma (test) vs saline (placebo) in patients with covid-related post-viral olfactory dysfunction.

the investigators hypothesize that the use of topical prp will improve smell identification, threshold, and smell-related quality of life in comparison to a placebo. this study will provide critical information for a promising new treatment of olfactory dysfunction with the highest level of evidence, in a randomized, placebo-controlled trial. preliminary results from an ongoing pilot study investigating topical prp is the basis for the hypothesis. by investigating the efficacy of topical prp in smell restoration, the investigators will provide a less-invasive way to deliver this autologous product. a randomized trial will set a precedent for the use of this treatment to serve a growing population of patients affected with post-covid olfactory dysfunction. over a period of one year, participants with post-viral olfactory dysfunction will be randomly assigned to a test or control group and will visit the clinic monthly for three months to receive prp or saline based on their randomized group. this will be followed by 9 months of at-home electronic visits. at each visit both the test and control groups will undergo smell testing and will fill quality of life questionnaire.

Eligibility criteria:
inclusion criteria: * adult patients suffering from either post-viral or post-covid smell loss of any duration, without a history of nasal surgery, nasal polyposis, chronic rhinosinusitis, or intranasal tumors * patients who are post-covid must report at least a positive home test on history * patients with post-viral etiology must have recall of a viral illness that immediately preceded smell loss exclusion criteria: * history of olfactory dysfunction predating covid-19 infection * history of trauma, previous surgery, or obstructive cause of od (nasal polyps, chronic rhinosinusitis) * pregnancy * patients who are unable to provide consent * patients with known bleeding disorders * patients with known malignancies

Keywords: olfaction smell
a phase iii study to efficacy and safety of dwc202405/dwc202313 and dwc202314 in patients with hypertension

Conditions: Essential Hypertension

Summary: a multi-center, randomized, double-blind, parallel design, phase iii study to evaluate and compare the efficacy and safety of dwc202405/dwc202313 and dwc202314 combination therapy to dwc202405/dwc202313 in patients with essential hypertension inadequately controlled with dwc202405


Eligibility criteria:
inclusion criteria: * average systolic blood pressure (mssbp) and average diastolic blood pressure (msdbp) measured at the time of screening meet the following criteria (a) if antihypertensive drugs are being administered: 140 mmhg ≤ mssbp \< 180 mmhg and msdbp \< 110 mmhg however, the criteria of 130 mmhg ≤ mssbp \< 180 mmhg and msdbp \< 110 mmhg are applied to patients with the following diseases. exclusion criteria: * if the blood pressure measured at the time of screening and randomization is mssbp ≥ 180 mmhg or msdbp ≥ 110 mmhg * those whose blood pressure differences measured on both arms at the time of screening are mssbp ≥ 20 mmhg and msdbp ≥ 10 mmhg
physical activity barriers in aecopd

Conditions: COPD Exacerbation

Summary: chronic obstructive pulmonary disease (copd) is a leading cause of morbidity and mortality worldwide. patients require good communication with the physician to improve control illness. shared decision making is a good option to improve physical activity barriers in acute exacerbated copd patients during the hospitalization period.


Eligibility criteria:
inclusion criteria: * inclusion criteria were copd patients hospitalized due to acute exacerbation exclusion criteria: * exclusion criteria were the inability to provide informed consent, the presence of psychiatric or cognitive disorders, progressive neurological disorders, organ failure, cancer, or inability to cooperate. patients who had experienced another exacerbation of copd in the previous month were also excluded.
optimal lidocaine buffering to reduce injection pain in local anesthesia

Conditions: Local Anesthesia

Summary: the purpose of this study is to determine the optimal amount of lidocaine buffering needed to decrease injection pain when administering local anesthesia.

once the site is chosen, the skin will be anesthetized as usual. this study will utilize a commercially prepared 1% lidocaine solution mixed with standard sodium bicarbonate. a total of 10 ml will be used.

Eligibility criteria:
inclusion criteria: * adults presenting for routine thyroid biopsy, paracentesis or thoracentesis in interventional radiology exclusion criteria: * patients requiring sedation * patients with altered mental status * children * patients allergic to lidocaine or sodium bicarbonate
a study to compare the menstrual bleeding profile among jaydess® and copper intrauterine device (iud) users. colibri study (copper and levonorgestrel iud barcelona research initiative).

Conditions: Contraception

Summary: the intrauterine device (iud) is a long-term birth control method that has demonstrated high contraceptive efficacy and effectiveness due to its high compliance, adherence and persistence of use. the iud has a global prevalence rate around 14% in women of reproductive age. side effects are the main reason for iud use discontinuation. the most common reasons for copper iud discontinuation are increased menstrual bleeding, irregular bleeding and dysmenorrhea, whereas in the case of 52mg levonorgestrel iud are irregular bleeding and amenorrhea. in 2014, a new hormonal iud containing13,5mg of levonorgestrel was marketed in spain. there are many studies comparing the two levonorgestrel iuds. however, there is any study comparing the iud 13,5mg levonorgestrel with classic copper iuds. the hypothesis of this trial is that levonorgestrel (13,5mg) iud users have a menstrual bleeding pattern with fewer days than copper 380 mm2 iud users. this is a phase iv, national single-center, randomized 1: 1, single-blind, comparative, parallel controled trial.


Eligibility criteria:
inclusion criteria: * healthy female subject. * parous or nulliparous women aged between 18 and 45 years who ask for an iud as a contraceptive method. * history of regular cyclic menstrual periods ranged from 21 to 35 days with non-excessive menstrual blood loss. exclusion criteria: * absolute contraindications to iud use, according to the world health organization medical eligibility criteria. * contraindications to use 13,5 lng-iud. * anemia. * use of short or long-acting preparations containing sex hormones within the 12 weeks before the iud insertion. * known bleeding irregularities. * pregnancy or breast-feeding.
effect of visceral manipulation on pcos

Conditions: Polycystic Ovary Syndrome

Summary: the study was conducted to determine the effect of visceral manipulation on menstrual irregularities and hormonal profile in women with polycystic ovarian syndrome. thirty women were randomly and equally assigned into the group (a) (control group), who received a low caloric diet (1200 kcal/day) only for 3 months, and the group (b) (study group), who received visceral manipulation to the pelvic organs and the related structures in addition to the same low-calorie diet as the group (a). evaluations pre and post-study were done for body weight, bmi, female reproductive hormones, and menstruation-related problems.

the current study was conducted to determine the effect of visceral manipulation on menstrual irregularities and hormonal profile in women with polycystic ovarian syndrome (pcos). thirty women having pcos were chosen from the outpatient clinic of the faculty of physical therapy, cairo university. patients were randomly assigned into two groups equal in number. group (a) (control group), 15 pcos women received a low caloric diet (1200 kcal/day) for 3 months, while group (b) (study group), 15 pcos women received visceral manipulation to the pelvic organs and the related structures (8 sessions, once per week in the first month then once every other week for two months) in addition to the same low-calorie diet as the group (a). evaluations pre and post-study for body weight, body mass index, female reproductive hormones \[luteinizinghormone (lh), follicle-stimulating hormone (fsh) and lh/fsh ratio\] and menstruation-related problems were done by weight- height scale, blood analysis, and menstruation-specific domain of polycystic ovary syndrome health-related quality of life questionnaire (pcosq), respectively.

Eligibility criteria:
inclusion criteria: * women having pcos. * 25 ≤ bmi ≤ 30 kg/m2. * waist/hip ratio ≤ 0.80. * women experiencing irregular menstrual cycles. exclusion criteria: * having cardiovascular diseases, diabetes mellitus, and/ or hypertension * having malignancy. * presence of reproductive disorders unrelated to pcos. * presence of adrenal gland abnormalities.

Keywords: polycystic ovary syndrome menstruation disturbances caloric restriction manipulation therapy
trilaciclib for the prevention of chemoradiotherapy-induced myelosuppression in esophageal squamous cell carcinoma

Conditions: ESCC

Summary: clinical data of patients with synchronous radiotherapy for esophageal cancer in the department of radiology of jiangsu provincial people's hospital were collected. patients were divided into trilaciclib group (34 cases) and control group (169 cases) based on whether trilaciclib was used or not. patients in the trilaciclib group were given trilaciclib before each chemotherapy treatment. propensity score matching (psm) was used to balance the baseline characteristics between the two groups on a 1:1 ratio. after pairing, the rates of bone marrow suppression and other adverse events were compared between the two groups.

chemoradiotherapy-induced myelosuppression (cim) is the most common adverse event of concurrent chemoradiotherapy for esophageal cancer, often leading to reduction, delay or even cessation of chemotherapeutic agents. clinical treatments for cim mainly include various hematopoietic growth factors and blood transfusion. however, these interventions target only a single spectrum of blood cells and are susceptible to concomitant adverse events such as bone pain, thrombosis, and fever. trilaciclib is a potent, transient, reversible cdk4/6 inhibitor and is the world's first innovative drug with lineage-wide myeloprotective effects. its use in esophageal cancer has not been reported yet. in this study, we investigated the clinical efficacy and safety of trilaciclib in preventing myelosuppression in concurrent chemoradiotherapy for esophageal cancer for the first time.

Eligibility criteria:
inclusion criteria: * age ≥18 years; * pathological diagnosis of esophageal squamous cell carcinoma; * failure to undergo surgical treatment; * completion of definitive chemoradiotherapy or chemoradiotherapy combined with immunotherapy. exclusion criteria: * history of other malignant tumors; * difficulty in follow-up; * insufficient clinical information.

Keywords: trilaciclib